Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

Free Abstracts

  Arrhythmias

  Free Subscription


Articles published in Eur Heart J

Retrieve available abstracts of 155 articles:
HTML format
Text format



Single Articles


    April 2018
  1. GOLWALA HB, Cannon CP, Steg PG, Doros G, et al
    Safety and efficacy of dual vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of randomized clinical trials.
    Eur Heart J. 2018 Apr 13. pii: 4970508. doi: 10.1093.
    PubMed     Text format     Abstract available


  2. EZEKOWITZ MD, Pollack CV Jr, Halperin JL, England RD, et al
    Apixaban compared to heparin/vitamin K antagonist in patients with atrial fibrillation scheduled for cardioversion: the EMANATE trial.
    Eur Heart J. 2018 Apr 6. pii: 4963487. doi: 10.1093.
    PubMed     Text format     Abstract available


    March 2018
  3. POKORNEY SD, Daubert JP
    Atrial fibrillation ablation alone or atrial fibrillation ablation plus an antiarrhythmic drug?
    Eur Heart J. 2018 Mar 27. pii: 4955289. doi: 10.1093.
    PubMed     Text format    


  4. KIRCHHOF P, Haeusler KG, Blank B, De Bono J, et al
    Apixaban in patients at risk of stroke undergoing atrial fibrillation ablation.
    Eur Heart J. 2018 Mar 20. pii: 4943979. doi: 10.1093.
    PubMed     Text format     Abstract available


  5. STEFFEL J, Verhamme P, Potpara TS, Albaladejo P, et al
    The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation.
    Eur Heart J. 2018 Mar 17. pii: 4942493. doi: 10.1093.
    PubMed     Text format     Abstract available


  6. WALDMANN V, Bougouin W, Karam N, Dumas F, et al
    Characteristics and clinical assessment of unexplained sudden cardiac arrest in the real-world setting: focus on idiopathic ventricular fibrillation.
    Eur Heart J. 2018 Mar 16. pii: 4939309. doi: 10.1093.
    PubMed     Text format     Abstract available


  7. HASEGAWA K, Kaseno K, Aiki T, Tada H, et al
    Left atrial sarcoidosis as a substrate for peri-mitral atrial flutter: an unusual, underlying atrial disease.
    Eur Heart J. 2018 Mar 15. pii: 4938722. doi: 10.1093.
    PubMed     Text format    


    February 2018
  8. LANCELLOTTI P, Galderisi M
    Prediction of ischaemic stroke in non-valvular atrial fibrillation if advanced echocardiography plays the game.
    Eur Heart J. 2018 Feb 9. pii: 4847811. doi: 10.1093.
    PubMed     Text format    


  9. RIENSTRA M, Hobbelt AH, Alings M, Tijssen JGP, et al
    Targeted therapy of underlying conditions improves sinus rhythm maintenance in patients with persistent atrial fibrillation: results of the RACE 3 trial.
    Eur Heart J. 2018 Feb 1. pii: 4786620. doi: 10.1093.
    PubMed     Text format     Abstract available


    January 2018
  10. MAHAJAN R, Perera T, Elliott AD, Twomey DJ, et al
    Subclinical device-detected atrial fibrillation and stroke risk: a systematic review and meta-analysis.
    Eur Heart J. 2018 Jan 10. pii: 4797540. doi: 10.1093.
    PubMed     Text format     Abstract available


  11. HEALEY JS
    The winding path towards rationale anti-thrombotic therapy to prevent stroke in patients with atrial fibrillation.
    Eur Heart J. 2018 Jan 9. pii: 4796907. doi: 10.1093.
    PubMed     Text format    


  12. LIP GYH, Lane DA, Potpara TS
    Innovative strategies to improve adherence to non-vitamin K antagonist oral anticoagulants for stroke prevention in atrial fibrillation.
    Eur Heart J. 2018 Jan 6. pii: 4791955. doi: 10.1093.
    PubMed     Text format    


  13. DESTEGHE L, Vijgen J, Koopman P, Dilling-Boer D, et al
    Telemonitoring-based feedback improves adherence to non-vitamin K antagonist oral anticoagulants intake in patients with atrial fibrillation.
    Eur Heart J. 2018 Jan 2. pii: 4782504. doi: 10.1093.
    PubMed     Text format     Abstract available


    December 2017
  14. LEUNG M, van Rosendael PJ, Abou R, Ajmone Marsan N, et al
    Left atrial function to identify patients with atrial fibrillation at high risk of stroke: new insights from a large registry.
    Eur Heart J. 2017 Dec 28. pii: 4781364. doi: 10.1093.
    PubMed     Text format     Abstract available


  15. VERHEUGT FWA, Gao H, Al Mahmeed W, Ambrosio G, et al
    Characteristics of patients with atrial fibrillation prescribed antiplatelet monotherapy compared with those on anticoagulants: insights from the GARFIELD-AF registry.
    Eur Heart J. 2017 Dec 20. pii: 4769347. doi: 10.1093.
    PubMed     Text format     Abstract available


  16. POKORNEY SD, Granger CB
    Traumatic injury: another unjustified reason to stop oral anticoagulation for atrial fibrillation.
    Eur Heart J. 2017 Dec 13. pii: 4735276. doi: 10.1093.
    PubMed     Text format    


  17. DUYTSCHAEVER M, Demolder A, Phlips T, Sarkozy A, et al
    PulmOnary vein isolation With vs. without continued antiarrhythmic Drug trEatment in subjects with Recurrent Atrial Fibrillation (POWDER AF): results from a multicentre randomized trial.
    Eur Heart J. 2017 Dec 2. pii: 4683714. doi: 10.1093.
    PubMed     Text format     Abstract available


    November 2017
  18. SPOSATO LA, Lopes RD
    Oral anticoagulation: a step toward solving the puzzle of dementia related to atrial fibrillation?
    Eur Heart J. 2017 Nov 27. pii: 4665696. doi: 10.1093.
    PubMed     Text format    


  19. PICCINI JP, Kirchhof P
    Improving outcomes after catheter ablation of atrial fibrillation: better patient selection, better procedure, or both?
    Eur Heart J. 2017 Nov 22. pii: 4652880. doi: 10.1093.
    PubMed     Text format    


  20. STAERK L, Fosbol EL, Lamberts M, Bonde AN, et al
    Resumption of oral anticoagulation following traumatic injury and risk of stroke and bleeding in patients with atrial fibrillation: a nationwide cohort study.
    Eur Heart J. 2017 Nov 18. doi: 10.1093.
    PubMed     Text format     Abstract available


    October 2017
  21. FRIBERG L, Rosenqvist M
    Less dementia with oral anticoagulation in atrial fibrillation.
    Eur Heart J. 2017 Oct 24. doi: 10.1093.
    PubMed     Text format     Abstract available


  22. LIP GYH, Lane DA, Sarwar S
    Streamlining primary and secondary care management pathways for stroke prevention in atrial fibrillation.
    Eur Heart J. 2017;38:2980-2982.
    PubMed     Text format    


  23. HIJAZI Z, Oldgren J, Lindback J, Alexander JH, et al
    A biomarker-based risk score to predict death in patients with atrial fibrillation: the ABC (age, biomarkers, clinical history) death risk score.
    Eur Heart J. 2017 Oct 21. doi: 10.1093.
    PubMed     Text format     Abstract available


  24. DELISLE BP, January CT
    Advancing precision medicine for the treatment of long-QT syndrome type 2: shedding light on lumacaftor.
    Eur Heart J. 2017 Oct 11. doi: 10.1093.
    PubMed     Text format    


    September 2017
  25. KOTECHA D, Kirchhof P
    ESC Apps for Atrial Fibrillation.
    Eur Heart J. 2017;38:2643-2645.
    PubMed     Text format    


  26. LUSCHER TF
    Risk factors and consequences of atrial fibrillation: genetics, blood pressure, working hours, and cognitive decline.
    Eur Heart J. 2017;38:2573-2575.
    PubMed     Text format    


  27. KIRCHHOF P, Sanders P
    My atrial fibrillation is not your atrial fibrillation.
    Eur Heart J. 2017;38:2608-2611.
    PubMed     Text format    


  28. MAHMOODI BK, Boersma LV
    Do long working hours predispose to atrial fibrillation?
    Eur Heart J. 2017;38:2629-2631.
    PubMed     Text format    


  29. KIVIMAKI M, Nyberg ST, Batty GD, Kawachi I, et al
    Long working hours as a risk factor for atrial fibrillation: a multi-cohort study.
    Eur Heart J. 2017;38:2621-2628.
    PubMed     Text format     Abstract available


    August 2017
  30. PALLISGAARD JL, Gislason GH, Hansen J, Johannessen A, et al
    Temporal trends in atrial fibrillation recurrence rates after ablation between 2005 and 2014: a nationwide Danish cohort study.
    Eur Heart J. 2017 Aug 28. doi: 10.1093.
    PubMed     Text format     Abstract available


  31. KIRCHHOF P, Schroeder S
    NOACs in Atrial Fibrillation.
    Eur Heart J. 2017;38:2382-2385.
    PubMed     Text format    


    July 2017
  32. MEHTA A, Ramachandra CJA, Singh P, Chitre A, et al
    Identification of a targeted and testable antiarrhythmic therapy for long-QT syndrome type 2 using a patient-specific cellular model.
    Eur Heart J. 2017 Jul 21. doi: 10.1093.
    PubMed     Text format     Abstract available


    June 2017
  33. LEE SS, Ae Kong K, Kim D, Lim YM, et al
    Clinical implication of an impaired fasting glucose and prehypertension related to new onset atrial fibrillation in a healthy Asian population without underlying disease: a nationwide cohort study in Korea.
    Eur Heart J. 2017 Jun 28. doi: 10.1093.
    PubMed     Text format     Abstract available


  34. HUANG H, Darbar D
    Genetic heterogeneity of atrial fibrillation susceptibility loci across racial or ethnic groups.
    Eur Heart J. 2017 Jun 14. doi: 10.1093.
    PubMed     Text format    


  35. DIENER HC
    Does atrial fibrillation lead to cognitive decline and dementia?
    Eur Heart J. 2017 Jun 14. doi: 10.1093.
    PubMed     Text format    


    May 2017
  36. LUSCHER TF
    Gender issues in arrhythmias: from atrial fibrillation to CRT and arrhythmogenic ventricular cardiomyopathy.
    Eur Heart J. 2017;38:1443-1446.
    PubMed     Text format    


    April 2017
  37. SINGH-MANOUX A, Fayosse A, Sabia S, Canonico M, et al
    Atrial fibrillation as a risk factor for cognitive decline and dementia.
    Eur Heart J. 2017 Apr 29. doi: 10.1093.
    PubMed     Text format     Abstract available


  38. LEE JY, Kim TH, Yang PS, Lim HE, et al
    Korean atrial fibrillation network genome-wide association study for early-onset atrial fibrillation identifies novel susceptibility loci.
    Eur Heart J. 2017 Apr 27. doi: 10.1093.
    PubMed     Text format     Abstract available


    March 2017
  39. RAHIMI K
    Subclinical atrial fibrillation in need of more assertive evidence.
    Eur Heart J. 2017 Mar 31. doi: 10.1093.
    PubMed     Text format    



  40. Corrigendum to: 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS'.
    Eur Heart J. 2017 Mar 27. doi: 10.1093.
    PubMed     Text format    


  41. CAMM AJ, Savelieva I
    Female gender as a risk factor for stroke associated with atrial fibrillation.
    Eur Heart J. 2017 Mar 27. doi: 10.1093.
    PubMed     Text format    


  42. LUSCHER TF
    Atrial fibrillation and thrombo- embolism: anticoagulants or devices?
    Eur Heart J. 2017;38:839-842.
    PubMed     Text format    


  43. ABDUL-RAHIM AH, Perez AC, MacIsaac RL, Jhund PS, et al
    Risk of stroke in chronic heart failure patients with preserved ejection fraction, but without atrial fibrillation: analysis of the CHARM-Preserved and I-Preserve trials.
    Eur Heart J. 2017;38:742-750.
    PubMed     Text format     Abstract available


  44. VAN GELDER IC, Healey JS, Crijns HJ, Wang J, et al
    Duration of device-detected subclinical atrial fibrillation and occurrence of stroke in ASSERT.
    Eur Heart J. 2017 Mar 1. doi: 10.1093.
    PubMed     Text format     Abstract available


    February 2017
  45. SHUN-SHIN MJ, Zheng SL, Cole GD, Howard JP, et al
    Implantable cardioverter defibrillators for primary prevention of death in left ventricular dysfunction with and without ischaemic heart disease: a meta-analysis of 8567 patients in the 11 trials.
    Eur Heart J. 2017 Feb 21. doi: 10.1093.
    PubMed     Text format     Abstract available


  46. AKDIS D, Saguner AM, Shah K, Wei C, et al
    Sex hormones affect outcome in arrhythmogenic right ventricular cardiomyopathy/dysplasia: from a stem cell derived cardiomyocyte-based model to clinical biomarkers of disease outcome.
    Eur Heart J. 2017 Feb 18. doi: 10.1093.
    PubMed     Text format     Abstract available


  47. BACANOVIC S, Steffen C, Benz DC, Kaufmann PA, et al
    Third-degree atrioventricular block: tip of the iceberg of a systemic disease.
    Eur Heart J. 2017 Feb 14. doi: 10.1093.
    PubMed     Text format    


    January 2017
  48. GADSBOLL K, Staerk L, Fosbol EL, Sindet-Pedersen C, et al
    Increased use of oral anticoagulants in patients with atrial fibrillation: temporal trends from 2005 to 2015 in Denmark.
    Eur Heart J. 2017 Jan 21. pii: ehw658. doi: 10.1093.
    PubMed     Text format     Abstract available


  49. SCHWARTZ PJ
    Evolving concepts for the Long QT Syndrome.
    Eur Heart J. 2017;38:225-226.
    PubMed     Text format    


  50. STEFFEL J
    The Subcutaneous Implantable Cardioverter Defibrillator.
    Eur Heart J. 2017;38:226-228.
    PubMed     Text format    


  51. MCLEOD CJ, Boersma L, Okamura H, Friedman PA, et al
    The subcutaneous implantable cardioverter defibrillator: state-of-the-art review.
    Eur Heart J. 2017;38:247-257.
    PubMed     Text format    


  52. ARBELO E, Brugada J, Lundqvist CB, Laroche C, et al
    Contemporary management of patients undergoing atrial fibrillation ablation: in-hospital and 1-year follow-up findings from the ESC-EHRA atrial fibrillation ablation long-term registry.
    Eur Heart J. 2017 Jan 18. pii: ehw564. doi: 10.1093.
    PubMed     Text format     Abstract available


  53. RENOUX C, Coulombe J, Suissa S
    Revisiting sex differences in outcomes in non-valvular atrial fibrillation: a population-based cohort study.
    Eur Heart J. 2017 Jan 10. pii: ehw613. doi: 10.1093.
    PubMed     Text format     Abstract available


  54. BAVENDIEK U, Aguirre Davila L, Koch A, Bauersachs J, et al
    Assumption versus evidence: the case of digoxin in atrial fibrillation and heart failure.
    Eur Heart J. 2017 Jan 8. pii: ehw577. doi: 10.1093.
    PubMed     Text format    


  55. CHATTERJEE NA, Borgquist R, Chang Y, Lewey J, et al
    Increasing sex differences in the use of cardiac resynchronization therapy with or without implantable cardioverter-defibrillator.
    Eur Heart J. 2017 Jan 8. pii: ehw598. doi: 10.1093.
    PubMed     Text format     Abstract available


  56. FANOLA CL, Giugliano RP, Ruff CT, Trevisan M, et al
    A novel risk prediction score in atrial fibrillation for a net clinical outcome from the ENGAGE AF-TIMI 48 randomized clinical trial.
    Eur Heart J. 2017 Jan 6. pii: ehw565. doi: 10.1093.
    PubMed     Text format     Abstract available


  57. SCHMIDT C, Wiedmann F, Zhou XB, Heijman J, et al
    Inverse remodelling of K2P3.1 K+ channel expression and action potential duration in left ventricular dysfunction and atrial fibrillation: implications for patient-specific antiarrhythmic drug therapy.
    Eur Heart J. 2017 Jan 4. pii: ehw559. doi: 10.1093.
    PubMed     Text format     Abstract available


  58. NATTEL S
    Close connections between contraction and rhythm: a new genetic cause of atrial fibrillation/cardiomyopathy and what it can teach us.
    Eur Heart J. 2017;38:35-37.
    PubMed     Text format    


  59. GRACE A, Verma A, Willems S
    Dipole Density Mapping of Atrial Fibrillation.
    Eur Heart J. 2017;38:5-9.
    PubMed     Text format    


  60. LIP GY
    Stroke prevention in Atrial Fibrillation.
    Eur Heart J. 2017;38:4-5.
    PubMed     Text format    


  61. LUSCHER TF
    Atrial fibrillation beyond the arrhythmia: hypercoagulability, adipose tissue, and fibrotic remodelling.
    Eur Heart J. 2017;38:1-3.
    PubMed     Text format    


  62. GAL P, Marrouche NF
    Magnetic resonance imaging of atrial fibrosis: redefining atrial fibrillation to a syndrome.
    Eur Heart J. 2017;38:14-19.
    PubMed     Text format     Abstract available


    December 2016
  63. NYNS EC, Kip A, Bart CI, Plomp JJ, et al
    Optogenetic termination of ventricular arrhythmias in the whole heart: towards biological cardiac rhythm management.
    Eur Heart J. 2016 Dec 23. pii: ehw574. doi: 10.1093.
    PubMed     Text format     Abstract available


  64. DURU F, Brunckhorst C
    Zurich International Symposium on Arrhythmogenic Right Ventricular Cardiomyopathies.
    Eur Heart J. 2016;37:3555-3556.
    PubMed     Text format    


  65. WAHBI K, Babuty D, Probst V, Wissocque L, et al
    Incidence and predictors of sudden death, major conduction defects and sustained ventricular tachyarrhythmias in 1388 patients with myotonic dystrophy type 1.
    Eur Heart J. 2016.
    PubMed     Text format     Abstract available


  66. WAHBI K, Babuty D, Probst V, Wissocque L, et al
    Incidence and predictors of sudden death, major conduction defects and sustained ventricular tachyarrhythmias in 1388 patients with myotonic dystrophy type 1.
    Eur Heart J. 2016 Dec 9. doi: 10.1093.
    PubMed     Text format    


    October 2016
  67. HALVORSEN S, Storey RF, Rocca B, Sibbing D, et al
    Management of antithrombotic therapy after bleeding in patients with coronary artery disease and/or atrial fibrillation: expert consensus paper of the European Society of Cardiology Working Group on Thrombosis.
    Eur Heart J. 2016.
    PubMed     Text format    


  68. TARANTINI G, Mojoli M, Urena M, Vahanian A, et al
    Atrial fibrillation in patients undergoing transcatheter aortic valve implantation: epidemiology, timing, predictors, and outcome.
    Eur Heart J. 2016.
    PubMed     Text format     Abstract available


  69. GUDBJARTSSON DF, Holm H, Sulem P, Masson G, et al
    A frameshift deletion in the sarcomere gene MYL4 causes early-onset familial atrial fibrillation.
    Eur Heart J. 2016.
    PubMed     Text format     Abstract available


  70. STAERK L, Fosbol EL, Lip GY, Lamberts M, et al
    Ischaemic and haemorrhagic stroke associated with non-vitamin K antagonist oral anticoagulants and warfarin use in patients with atrial fibrillation: a nationwide cohort study.
    Eur Heart J. 2016.
    PubMed     Text format     Abstract available



  71. Yoga and atrial fibrillation.
    Eur Heart J. 2016;37:2855.
    PubMed     Text format    



  72. 'Ten Commandments' of 2016 ESC Guidelines for the management of atrial fibrillation.
    Eur Heart J. 2016;37:2853.
    PubMed     Text format    



  73. What's new in the 2016 ESC Guidelines on atrial fibrillation?
    Eur Heart J. 2016;37:2851-2852.
    PubMed     Text format    


  74. LUSCHER TF
    Atrial fibrillation: today's guideline-based management.
    Eur Heart J. 2016;37:2847-2850.
    PubMed     Text format    


    September 2016
  75. IBRAHIM T, Dommasch M, Huber A, Hoppmann P, et al
    Percutaneous revascularization of concurrently obstructed left-sided pulmonary veins complicating catheter ablation for atrial fibrillation.
    Eur Heart J. 2016.
    PubMed     Text format    


  76. ZAMORANO JL
    Specific risk of atrial fibrillation and stroke in oncology patients.
    Eur Heart J. 2016;37:2747-2748.
    PubMed     Text format    


  77. KOYAMA M, Yano T, Kikuchi K, Nagahara D, et al
    Lethal heart failure with anti-mitochondrial antibody: an arrhythmogenic right ventricular cardiomyopathy mimetic.
    Eur Heart J. 2016.
    PubMed     Text format    


    August 2016
  78. KIRCHHOF P, Benussi S, Kotecha D, Ahlsson A, et al
    2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS: The Task Force for the management of atrial fibrillation of the European Society of Cardiology (ESC)Developed with the special contribution of the Eur
    Eur Heart J. 2016.
    PubMed     Text format    


  79. LUSCHER TF
    Atrial fibrillation and stroke: risk factors, anticoagulation, and left atrial appendage occluders.
    Eur Heart J. 2016;37:2443-5.
    PubMed     Text format    


    July 2016
  80. BUNCH TJ, May HT
    Atrial fibrillation: a risk factor or risk marker?
    Eur Heart J. 2016.
    PubMed     Text format    


  81. LAU DH, Middeldorp ME, Sanders P
    Obesity paradox in atrial fibrillation: a distracting reality or fictitious finding?
    Eur Heart J. 2016.
    PubMed     Text format    


  82. KIRCHHOF P, Calkins H
    Catheter ablation in patients with persistent atrial fibrillation.
    Eur Heart J. 2016.
    PubMed     Text format     Abstract available


  83. KUCK KH, Furnkranz A, Chun KR, Metzner A, et al
    Cryoballoon or radiofrequency ablation for symptomatic paroxysmal atrial fibrillation: reintervention, rehospitalization, and quality-of-life outcomes in the FIRE AND ICE trial.
    Eur Heart J. 2016.
    PubMed     Text format     Abstract available


    June 2016
  84. BASSAND JP, Accetta G, Camm AJ, Cools F, et al
    Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF.
    Eur Heart J. 2016.
    PubMed     Text format     Abstract available


  85. HEIDBUCHEL H, Verhamme P, Alings M, Antz M, et al
    Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: Executive summary.
    Eur Heart J. 2016.
    PubMed     Text format     Abstract available


  86. FERREIRA JP, Girerd N, Alshalash S, Konstam MA, et al
    Antithrombotic therapy in heart failure patients with and without atrial fibrillation: update and future challenges.
    Eur Heart J. 2016.
    PubMed     Text format     Abstract available


    May 2016
  87. LUSCHER TF
    Atrial fibrillation: novel risk factors, mechanisms and ablation techniques.
    Eur Heart J. 2016;37:1553-5.
    PubMed     Text format    


    April 2016
  88. BADIMON L, Cubedo J
    Hypercoagulability and atrial fibrillation: a two-way road?
    Eur Heart J. 2016.
    PubMed     Text format    


  89. SPRONK HM, De Jong AM, Verheule S, De Boer HC, et al
    Hypercoagulability causes atrial fibrosis and promotes atrial fibrillation.
    Eur Heart J. 2016.
    PubMed     Text format     Abstract available


  90. SANDHU RK, Ezekowitz J, Andersson U, Alexander JH, et al
    The 'obesity paradox' in atrial fibrillation: observations from the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial.
    Eur Heart J. 2016.
    PubMed     Text format     Abstract available


  91. NIELSEN JC, Gerdes JC
    Does catheter ablation reduce mortality and stroke in patients with atrial fibrillation? Patient selection or causality?
    Eur Heart J. 2016.
    PubMed     Text format    


  92. SCHMIDT M, Lamberts M, Olsen AM, Fosboll E, et al
    Cardiovascular safety of non-aspirin non-steroidal anti-inflammatory drugs: review and position paper by the working group for Cardiovascular Pharmacotherapy of the European Society of Cardiology.
    Eur Heart J. 2016;37:1015-23.
    PubMed     Text format    


    March 2016
  93. YOSHINAGA M, Kucho Y, Nishibatake M, Ogata H, et al
    Probability of diagnosing long QT syndrome in children and adolescents according to the criteria of the HRS/EHRA/APHRS expert consensus statement.
    Eur Heart J. 2016.
    PubMed     Text format     Abstract available


  94. CAIRNS JA
    The search for the ideal atrial fibrillation stroke risk prediction schema: is ATRIA a contender?
    Eur Heart J. 2016.
    PubMed     Text format    


  95. CHEN Y, Zheng M, Lin K, Cui K, et al
    Mapping and surgical ablation of persistent atrial fibrillation in cor triatriatum sinister.
    Eur Heart J. 2016.
    PubMed     Text format    


  96. FRIBERG L, Tabrizi F, Englund A
    Catheter ablation for atrial fibrillation is associated with lower incidence of stroke and death: data from Swedish health registries.
    Eur Heart J. 2016.
    PubMed     Text format     Abstract available


  97. FOX KA
    CardioPulse: Anticoagulants reduce risk of death in atrialfibrillation patients by 38%.
    Eur Heart J. 2016;37:860-1.
    PubMed     Text format    


  98. MORSETH B, Graff-Iversen S, Jacobsen BK, Jorgensen L, et al
    Physical activity, resting heart rate, and atrial fibrillation: the Tromso Study.
    Eur Heart J. 2016.
    PubMed     Text format     Abstract available


  99. ASPBERG S, Chang Y, Atterman A, Bottai M, et al
    Comparison of the ATRIA, CHADS2, and CHA2DS2-VASc stroke risk scores in predicting ischaemic stroke in a large Swedish cohort of patients with atrial fibrillation.
    Eur Heart J. 2016.
    PubMed     Text format     Abstract available


  100. WONG CX, Ganesan AN, Selvanayagam JB
    Epicardial fat and atrial fibrillation: current evidence, potential mechanisms, clinical implications, and future directions.
    Eur Heart J. 2016.
    PubMed     Text format     Abstract available


  101. DILLER GP, Brautigam A, Kempny A, Uebing A, et al
    Depression requiring anti-depressant drug therapy in adult congenital heart disease: prevalence, risk factors, and prognostic value.
    Eur Heart J. 2016;37:771-82.
    PubMed     Text format     Abstract available


    February 2016
  102. HIJAZI Z, Lindback J, Alexander JH, Hanna M, et al
    The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation.
    Eur Heart J. 2016.
    PubMed     Text format     Abstract available


  103. SOTO-RUIZ RM, Bonaque Gonzalez JC, Fernandez Gasso L, Castillo Moreno JA, et al
    Persistent mitral and tricuspid insufficiency.
    Eur Heart J. 2016;37:712.
    PubMed     Text format    


  104. GANESAN AN, Chew DP, Hartshorne T, Selvanayagam JB, et al
    The impact of atrial fibrillation type on the risk of thromboembolism, mortality, and bleeding: a systematic review and meta-analysis.
    Eur Heart J. 2016.
    PubMed     Text format     Abstract available



  105. CardioPulse: Ear stimulation for atrial fibrillation favoured at ESC Congress London.
    Eur Heart J. 2016;37:586.
    PubMed     Text format    


  106. TRUCHANOWICZ E, Kirchhof P
    CardioPulse: New perspectives for stroke prevention in atrial fibrillation.
    Eur Heart J. 2016;37:583-4.
    PubMed     Text format    


  107. TOFIELD A
    CardioPulse: Syncope and near drowning may signal sudden death risk.
    Eur Heart J. 2016;37:585.
    PubMed     Text format    


  108. OZKAN J
    CardioPulse: Gerhard Hindricks MD.
    Eur Heart J. 2016;37:580-1.
    PubMed     Text format    


  109. LUSCHER TF
    Managing arrhythmias: diagnosis and modern treatment.
    Eur Heart J. 2016;37:577-9.
    PubMed     Text format    


  110. STEFFEL J, Jais P, Hindricks G
    The year in cardiology 2015: arrhythmias and device therapy.
    Eur Heart J. 2016;37:587-93.
    PubMed     Text format    


  111. TANAWUTTIWAT T, Nazarian S, Calkins H
    The role of catheter ablation in the management of ventricular tachycardia.
    Eur Heart J. 2016;37:594-609.
    PubMed     Text format     Abstract available


  112. ANNEKEN L, Baumann S, Vigneault P, Biliczki P, et al
    Estradiol regulates human QT-interval: acceleration of cardiac repolarization by enhanced KCNH2 membrane trafficking.
    Eur Heart J. 2016;37:640-50.
    PubMed     Text format     Abstract available


  113. KAMAKURA T, Wada M, Nakajima I, Ishibashi K, et al
    Significance of electrocardiogram recording in high intercostal spaces in patients with early repolarization syndrome.
    Eur Heart J. 2016;37:630-7.
    PubMed     Text format     Abstract available


  114. KOCH J, Lucke C, Gebauer R, Hindricks G, et al
    Accessory pathway ablation in childhood forming the substrate for ventricular tachycardia in adulthood.
    Eur Heart J. 2016;37:609.
    PubMed     Text format    


  115. STROKER E, de Asmundis C, Chierchia GB, Brugada P, et al
    Exercise-related Brugada pattern and monomorphic ventricular tachycardia in a patient with Brugada syndrome: interplay between body temperature, haemodynamics and vagal activity.
    Eur Heart J. 2016;37:655.
    PubMed     Text format    


  116. WEBB J, Frigiola A, Carr-White G, Chiribiri A, et al
    An unusual cause of ventricular tachycardia.
    Eur Heart J. 2016;37:654.
    PubMed     Text format    


  117. VEHMEIJER JT, Brouwer TF, Limpens J, Knops RE, et al
    Implantable cardioverter-defibrillators in adults with congenital heart disease: a systematic review and meta-analysis.
    Eur Heart J. 2016.
    PubMed     Text format     Abstract available


  118. AUER J
    Fat: an emerging player in the field of atrial fibrillation.
    Eur Heart J. 2016.
    PubMed     Text format    


  119. DIENER HC, Aisenberg J, Ansell J, Atar D, et al
    Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 2.
    Eur Heart J. 2016.
    PubMed     Text format     Abstract available


  120. DIENER HC, Aisenberg J, Ansell J, Atar D, et al
    Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 1.
    Eur Heart J. 2016.
    PubMed     Text format     Abstract available


  121. SINGH SM, d'Avila A, Kim YH, Aryana A, et al
    The modified stepwise ablation guided by low-dose ibutilide in chronic atrial fibrillation trial (The MAGIC-AF Study).
    Eur Heart J. 2016.
    PubMed     Text format     Abstract available


  122. DIENER HC, Aisenberg J, Ansell J, Atar D, et al
    Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 1.
    Eur Heart J. 2016 Feb 4. doi: 10.1093.
    PubMed     Text format    


  123. DIENER HC, Aisenberg J, Ansell J, Atar D, et al
    Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 2.
    Eur Heart J. 2016 Feb 4. doi: 10.1093.
    PubMed     Text format    


  124. AQUILA I, Garcia A, Fernandez-Golfin C, Zamorano JL, et al
    It paces right but not in the right space!
    Eur Heart J. 2016;37:496.
    PubMed     Text format    


    January 2016
  125. VERHEUGT FW
    CardioPulse: Triple therapy for percutaneous coronary intervention in atrial fibrillation: a nightmare.
    Eur Heart J. 2016;37:326-7.
    PubMed     Text format    


  126. POZZOLI A, Mazzone P, Benussi S, Alfieri O, et al
    Incomplete surgical exclusion of the left atrial appendage.
    Eur Heart J. 2016;37:188.
    PubMed     Text format    


    December 2015
  127. AMIN AS, Wilde AA
    Genetic screening in acquired long QT syndrome? CAUTION: proceed carefully.
    Eur Heart J. 2015.
    PubMed     Text format    


  128. ITOH H, Crotti L, Aiba T, Spazzolini C, et al
    The genetics underlying acquired long QT syndrome: impact for genetic screening.
    Eur Heart J. 2015.
    PubMed     Text format     Abstract available


  129. LUSCHER TF
    Supraventricular and ventricular arrhythmias.
    Eur Heart J. 2015;36:3215-7.
    PubMed     Text format    


    November 2015
  130. HAEMERS P, Hamdi H, Guedj K, Suffee N, et al
    Atrial fibrillation is associated with the fibrotic remodelling of adipose tissue in the subepicardium of human and sheep atria.
    Eur Heart J. 2015.
    PubMed     Text format     Abstract available


  131. LAU DH, Schotten U, Mahajan R, Antic NA, et al
    Novel mechanisms in the pathogenesis of atrial fibrillation: practical applications.
    Eur Heart J. 2015.
    PubMed     Text format     Abstract available


    September 2015
  132. TAYLOR J
    Uninterrupted novel oral anticoagulant therapy during atrial fibrillation ablation is safe.
    Eur Heart J. 2015;36:2272.
    PubMed     Text format    


    August 2015
  133. GORCSAN J 3RD, Sogaard P, Bax JJ, Singh JP, et al
    Association of persistent or worsened echocardiographic dyssynchrony with unfavourable clinical outcomes in heart failure patients with narrow QRS width: a subgroup analysis of the EchoCRT trial.
    Eur Heart J. 2015.
    PubMed     Text format     Abstract available


  134. GALIE N, Humbert M, Vachiery JL, Gibbs S, et al
    2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS)End
    Eur Heart J. 2015.
    PubMed     Text format    


  135. LUSCHER TF
    Novel aspects of heart failure: from combined neurohormal blockade to embryonic stem cells.
    Eur Heart J. 2015;36:1937-9.
    PubMed     Text format    


    July 2015
  136. STONE GW, Adams DH, Abraham WT, Kappetein AP, et al
    Clinical trial design principles and endpoint definitions for transcatheter mitral valve repair and replacement: part 2: endpoint definitions: A consensus document from the Mitral Valve Academic Research Consortium.
    Eur Heart J. 2015.
    PubMed     Text format     Abstract available


    June 2015
  137. LIMA DA SILVA G, Pinto FJ, Almeida AG
    Invasive cardiac aspergillosis presenting as complete heart block in a patient with acute lymphoblastic leukaemia.
    Eur Heart J. 2015;36:1555.
    PubMed     Text format    


  138. SHARMA S, Merghani A, Mont L
    Exercise and the heart: the good, the bad, and the ugly.
    Eur Heart J. 2015;36:1445-53.
    PubMed     Text format     Abstract available


  139. POKORNEY SD, Granger CB
    Should patients on vitamin K antagonists be treated differently?
    Eur Heart J. 2015;36:1431-3.
    PubMed     Text format    


  140. O'DONOGHUE ML, Ruff CT, Giugliano RP, Murphy SA, et al
    Edoxaban vs. warfarin in vitamin K antagonist experienced and naive patients with atrial fibrillationdagger.
    Eur Heart J. 2015;36:1470-7.
    PubMed     Text format     Abstract available


  141. SEMSARIAN C, Ingles J, Wilde AA
    Sudden cardiac death in the young: the molecular autopsy and a practical approach to surviving relatives.
    Eur Heart J. 2015;36:1290-6.
    PubMed     Text format     Abstract available


  142. ROELL W, Sinning JM, Werner N, Mellert F, et al
    How to re-shape a transcatheter heart valve.
    Eur Heart J. 2015;36:1287.
    PubMed     Text format    


    May 2015
  143. SAYED RH, Rogers D, Khan F, Wechalekar AD, et al
    A study of implanted cardiac rhythm recorders in advanced cardiac AL amyloidosis.
    Eur Heart J. 2015;36:1098-105.
    PubMed     Text format     Abstract available


    April 2015
  144. LUSCHER TF
    Arrhythmias, syncopy, and sudden death.
    Eur Heart J. 2015;36:829-31.
    PubMed     Text format    


  145. VENTECLEF N, Guglielmi V, Balse E, Gaborit B, et al
    Human epicardial adipose tissue induces fibrosis of the atrial myocardium through the secretion of adipo-fibrokines.
    Eur Heart J. 2015;36:795-805a.
    PubMed     Text format     Abstract available


    March 2015
  146. LUSCHER TF
    Heart failure: focus on co-morbidities, inflammation, and heart rate.
    Eur Heart J. 2015;36:635-7.
    PubMed     Text format    


  147. GLUKHOV AV, Kalyanasundaram A, Lou Q, Hage LT, et al
    Calsequestrin 2 deletion causes sinoatrial node dysfunction and atrial arrhythmias associated with altered sarcoplasmic reticulum calcium cycling and degenerative fibrosis within the mouse atrial pacemaker complex1.
    Eur Heart J. 2015;36:686-97.
    PubMed     Text format     Abstract available


  148. COTTENS D, Corteville B, Vanvinckenroye A, Schepens M, et al
    Moderate gradient with disproportional dyspnoea: multimodality imaging of funnel-shaped subaortic membrane.
    Eur Heart J. 2015;36:583.
    PubMed     Text format    


    February 2015
  149. LUBITZ SA, Singh JP
    Biventricular pacing: more is better!
    Eur Heart J. 2015;36:407-9.
    PubMed     Text format    


    January 2015
  150. LUSCHER TF
    Arrhythmias and pacing.
    Eur Heart J. 2015;36:131-2.
    PubMed     Text format    


  151. MURAKOSHI N, Xu D, Sairenchi T, Igarashi M, et al
    Prognostic impact of supraventricular premature complexes in community-based health checkups: the Ibaraki Prefectural Health Study.
    Eur Heart J. 2015;36:170-8.
    PubMed     Text format     Abstract available


  152. HEIDBUCHEL H, Hindricks G, Broadhurst P, Van Erven L, et al
    EuroEco (European Health Economic Trial on Home Monitoring in ICD Patients): a provider perspective in five European countries on costs and net financial impact of follow-up with or without remote monitoring.
    Eur Heart J. 2015;36:158-69.
    PubMed     Text format     Abstract available


  153. STOCKBURGER M, Boveda S, Moreno J, Da Costa A, et al
    Long-term clinical effects of ventricular pacing reduction with a changeover mode to minimize ventricular pacing in a general pacemaker population.
    Eur Heart J. 2015;36:151-7.
    PubMed     Text format     Abstract available


  154. BOGDAN S, Glikson M
    Physiological pacing: a moving target?
    Eur Heart J. 2015;36:141-2.
    PubMed     Text format    


    October 2014
  155. PELLICORI P, Zhang J, Lukaschuk E, Joseph AC, et al
    Left atrial function measured by cardiac magnetic resonance imaging in patients with heart failure: clinical associations and prognostic value.
    Eur Heart J. 2014.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Arrhythmias is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: